Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Complete Response Letters: Industry Prefers Communication Before Rather Than Docs After

27 Apr 2022

• By Derrick Gingery

File with padlock — The FDA used to offer review documents to sponsors who received CRs . • Source: Alamy

Related Content

Complete Response Letters: US FDA Trying To Identify Subsets For Public Release

17 Jan 2018

Complete Response Letters: US FDA Tells Congress Broader Disclosures To Sponsors Could Be ‘Chilling’

04 Feb 2022

Clinical Trial Diversity Measures Primed For Inclusion In US FDA User Fee Legislation

18 Mar 2022

Accelerated Approval Reform Proposals Worry Industry: ‘Science Doesn’t Move The Same Way’

18 Mar 2022

Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping

24 Mar 2022

Decorating The 'Christmas Tree’: US House Bills That Could Be Tacked Onto FDA User Fee Legislation

02 Apr 2022

US FDA’s Califf Says Publishing Complete Response Letters Could Help Fight Misinformation

27 Apr 2022

Vanda Sues US FDA For Documents Backing Complete Response For Hetlioz Jet Lag Indication

08 Apr 2022

Additional Topics

United States Complete Response Letters User Fees Regulation Legislation BioPharmaceutical

More from Complete Response Letters

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.